论文部分内容阅读
目的 探讨 WT1基因 m RNA表达与白血病的关系及其意义。方法 应用逆转录 -聚合酶链反应 (RT- PCR)法测定 6 8例不同类型白血病及其处于不同疾病阶段的患者 WT1基因的表达。结果 6 5 %初治和复发急性白血病者 WT1表达阳性 ,而治疗缓解期 12例中仅 1例 (8% )表达为阳性。 16例慢性粒细胞白血病 (CML )中的 7例 (44 % ) WT1表达阳性 ,其中 4例急变者全部为阳性 ,10名正常人及 10例非血液病患者的 WT1表达阴性。结论 WT1基因在各类型白血病中均能表达 ,表达水平与体内白血病细胞的数量有关 ,亦与白血病的病程进展等相关。因此 ,RT- PCR可作为化疗和骨髓移植后微小残留病(MRD)检测的敏感指标 ,也是研究白血病发生、发展和预测预后的手段。
Objective To investigate the relationship between WT1 gene m RNA expression and leukemia and its significance. Methods Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the expression of WT1 gene in 68 patients with different types of leukemia and their disease stages. Results The expression of WT1 was positive in 65% of patients with newly diagnosed and relapsed acute leukemia, but positive in only 1 (8%) of 12 patients in remission stage. Among 16 cases of chronic myeloid leukemia (CML), 7 cases (44%) were positive for WT1 expression, of which 4 cases were all positive for rapid change, and 10 cases of normal and 10 cases of non-hematological disease were negative for WT1 expression. Conclusion The WT1 gene is expressed in all types of leukemia, and the expression level is related to the number of leukemic cells in vivo. It is also related to the progression of leukemia. Therefore, RT-PCR can be used as a sensitive indicator for the detection of minimal residual disease (MRD) after chemotherapy and bone marrow transplantation. It is also a means to study the occurrence, development, and prognosis of leukemia.